Since 2003, the Cancéropôles have become part of the cancer research landscape in France enabling a better coordination of resources and means and breaking down barriers. They give rise to large-scale research networks and infrastructures fostering interdisciplinarity.

The 7 regional or interregional hubs named Cancéropôles bring together research units of scientific institutions (INSERM, CNRS, universities, CEA, ...), university hospitals, comprehensive cancer centers, pharmaceutical companies and biotech players.

Their goals are mainly: (1) structure and coordinate research between institutions, at regional and inter-regional levels, (2) define specific strategic orientations based on the fields of excellence of each Cancéropôle, (3) create synergies with innovation and economic development stakeholders and (4) ensure adequacy between regional and national R&D policies in oncology, as promoted by the French National Cancer Institute (INCa).

High-level quality research projects supported by the INCa through the Cancéropôles networks should allow to better understand the molecular mechanisms involved in oncogenesis which is crucial to define new therapeutic targets and to develop innovative treatments for the benefit of all patients.
The CLARA research network, composing a broad range of academic and clinical teams together (210) with a dense patchwork of large, mid-size and start-up companies, offers an excellent opportunity to develop cutting-edge translational cancer research. In addition, the involvement of several patients advocacy groups drives CLARA’s research in the search for innovative solutions against cancer to serve patients’ needs.

Contact : Peter PAUWELS, Executive Director  
E-mail : ppauwels@canceropole-clara.com

5 Regions (Alsace, Bourgogne, Champagne-Ardenne, Franche-Comté, Lorraine) are united for building an inter-regional cancer research network linked to European neighbours. With one goal: mobilizing resources and know-how for allowing 8 millions inhabitants to benefit of the most recent innovations.

Contact : Pr Pierre OUDET, Scientific Coordinator  
E-mail : pierre.oudet@chru-strasbourg.fr

Cancéropôle Grand Ouest associates 4 regions : Bretagne, Centre, Pays de la Loire and Poitou-Charentes. Laboratories from the main public research centers and physicians work together for the development of new tools of diagnosis and innovating treatment.

Scientific director : Pr Régis BATAILLE  
E-mail : Canceropole.Go@inserm.fr

Cancéropôle Grand Sud-Ouest (GSO) - Bordeaux, Limoges, Montpellier, Nîmes and Toulouse. The “Cancéropôle GSO” encompasses over 250 clinical and scientific teams, involved in translational research and the discovery and validation of new therapeutic targets.

Scientific director : Pr Josy REIFFERS  
E-mail : canceropole@canceropole-gso.org

Cancéropôle Ile-de-France (Paris region) is an academic body that federates universities, academic institutions, hospitals and the pharmaceutical industry in the Paris area. It represents nearly 50% of national research strength in oncology.

Contact : Pr Jean NAVARRO, President  
E-mail : contact@canceropole-idf.fr

The North-West Cancéropôle is an area of 10 millions inhabitants with four districts : Nord-Pas-de-Calais, Picardie, Haute and Basse Normandie. Its strategic project is based on the optimization of available resources (clinicians networks, research units and technological platforms) in order to develop ambitious translational research. Specific projects involve growing international collaboration with Bruxelles, Rotterdam and London.

President : Pr Pierre FORMSTECHER  
E-mail : pierre.formstecher@inserm.fr

1 000 researchers over 120 research teams & 25 technological platforms, combining basic science, medical research and innovation, across hospitals and university sites between Marseille & Nice (Provence Alpes Côte d’Azur Region)

Contact : Pr Jean-Paul BORG, Scientific Coordinator  
E-mail : canceropole-paca@medecine.univmed.fr